PE20150682A1 - Variantes de inmunoglobulinas y sus usos - Google Patents

Variantes de inmunoglobulinas y sus usos

Info

Publication number: PE20150682A1
Authority: PE; Peru
Prior art keywords: immunoglobulin variants; variants; immunoglobulin; lives; vivo
Prior art date: 2008-10-14

Application number

PE2015000431A

Other languages

English (en)

Spanish (es)

Inventor

Lisa A Damico

Napoleone Ferrara

Henry B Lowman

Yu-Ju G Meng

Yik Andy Yeung

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-10-14

Filing date

2009-10-13

Publication date

2015-05-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41571534&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20150682(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-10-13 Application filed by Genentech Inc filed Critical Genentech Inc

2015-05-20 Publication of PE20150682A1 publication Critical patent/PE20150682A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

PE2015000431A 2008-10-14 2009-10-13 Variantes de inmunoglobulinas y sus usos PE20150682A1 (es)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US10508608P	2008-10-14	2008-10-14
US15213109P	2009-02-12	2009-02-12
US17176809P	2009-04-22	2009-04-22
US22051409P	2009-06-25	2009-06-25

Publications (1)

Publication Number	Publication Date
PE20150682A1 true PE20150682A1 (es)	2015-05-20

Family

ID=41571534

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PE2015000431A PE20150682A1 (es)	2008-10-14	2009-10-13	Variantes de inmunoglobulinas y sus usos
PE2011000886A PE20110707A1 (es)	2008-10-14	2009-10-13	Variantes de inmunoglobulinas

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PE2011000886A PE20110707A1 (es)	2008-10-14	2009-10-13	Variantes de inmunoglobulinas

Country Status (21)

Country	Link
US (3)	US20100098730A1 (fr)
EP (2)	EP2352521B1 (fr)
JP (2)	JP5913980B2 (fr)
KR (3)	KR102100066B1 (fr)
CN (3)	CN110317272A (fr)
AR (1)	AR073829A1 (fr)
AU (1)	AU2009303526B2 (fr)
BR (1)	BRPI0914091B1 (fr)
CA (1)	CA2739429C (fr)
CL (1)	CL2015000148A1 (fr)
ES (1)	ES2828721T3 (fr)
IL (2)	IL212048B (fr)
MX (1)	MX2011004001A (fr)
PE (2)	PE20150682A1 (fr)
PH (1)	PH12016500081A1 (fr)
PL (1)	PL2352521T3 (fr)
RU (1)	RU2536937C2 (fr)
SG (2)	SG10201605250SA (fr)
TW (2)	TWI572359B (fr)
WO (1)	WO2010045193A1 (fr)
ZA (1)	ZA201102413B (fr)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7183387B1 (en)	1999-01-15	2007-02-27	Genentech, Inc.	Polypeptide variants with altered effector function
DK1443961T3 (da) *	2001-10-25	2009-08-24	Genentech Inc	Glycoprotein-sammensætninger
CA2587617C (fr)	2004-11-12	2011-02-01	Xencor, Inc.	Variants fc presentant une liaison modifiee au fcrn
CN101479381B (zh)	2006-03-31	2015-04-29	中外制药株式会社	调控抗体血液动力学的方法
US20080127996A1 (en) *	2006-12-04	2008-06-05	Weinhold Dennis G	Method and apparatus to remediate an acid and/or liquid spill
EP3127921A1 (fr)	2007-09-26	2017-02-08	Chugai Seiyaku Kabushiki Kaisha	Procédé de modification d'un anticorps par point isoélectrique par substitution d'acide aminé dans cdr
WO2009041613A1 (fr)	2007-09-26	2009-04-02	Chugai Seiyaku Kabushiki Kaisha	Région constante d'anticorps modifié
US12492253B1 (en)	2008-02-25	2025-12-09	Xencor, Inc.	Anti-human C5 antibodies
HUE067049T2 (hu)	2008-04-11	2024-09-28	Chugai Pharmaceutical Co Ltd	Két vagy több antigén-molekulát ismétlõdõen megkötni képes antigénkötõ molekula
TWI440469B (zh)	2008-09-26	2014-06-11	Chugai Pharmaceutical Co Ltd	Improved antibody molecules
EP2233500A1 (fr) *	2009-03-20	2010-09-29	LFB Biotechnologies	Variantes Fc optimisées
CA2757931C (fr)	2009-04-07	2019-03-26	Roche Glycart Ag	Anticorps trivalents bispecifiques
US9676845B2 (en)	2009-06-16	2017-06-13	Hoffmann-La Roche, Inc.	Bispecific antigen binding proteins
EP2478013B1 (fr)	2009-09-16	2018-10-24	F.Hoffmann-La Roche Ag	Complexes protéiques contenant une super-hélice et/ou une attache et leurs utilisations
RU2559542C2 (ru)	2009-12-23	2015-08-10	Дженентек, Инк.	Антитела против bv8 и их применение
AR080793A1 (es)	2010-03-26	2012-05-09	Roche Glycart Ag	Anticuerpos biespecificos
TWI667257B (zh) *	2010-03-30	2019-08-01	中外製藥股份有限公司	促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
WO2011133886A2 (fr)	2010-04-23	2011-10-27	Genentech, Inc.	Production de protéines hétéromultimères
BR112013001847A2 (pt)	2010-08-24	2016-05-31	Hoffmann La Roche	anticorpo biespecífico, método de preparação do anticorpo biespecífico, do anticorpo biespecífico trivalente, métodos e composição farmacêutica
CN103328632A (zh)	2010-11-30	2013-09-25	中外制药株式会社	与多分子的抗原重复结合的抗原结合分子
EP2655413B1 (fr)	2010-12-23	2019-01-16	F.Hoffmann-La Roche Ag	Complexe polypeptide-polynucléotide et son utilisation dans l'administration d'une fraction effectrice ciblée
US10689447B2 (en)	2011-02-04	2020-06-23	Genentech, Inc.	Fc variants and methods for their production
EP3604330A1 (fr)	2011-02-25	2020-02-05	Chugai Seiyaku Kabushiki Kaisha	Anticorps fc spécifique au fcgammariib
JP5768147B2 (ja)	2011-02-28	2015-08-26	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	一価抗原結合タンパク質
CN103502271B (zh)	2011-02-28	2016-10-26	霍夫曼-拉罗奇有限公司	抗原结合蛋白
CN105949313B (zh)	2011-03-29	2021-06-15	罗切格利卡特公司	抗体Fc变体
DK2728002T3 (da)	2011-06-30	2022-04-04	Chugai Pharmaceutical Co Ltd	Heterodimeriseret polypeptid
UA117901C2 (uk) *	2011-07-06	2018-10-25	Ґенмаб Б.В.	Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
KR20200120743A (ko) *	2011-07-06	2020-10-21	젠맵 비. 브이	항체 변이체 및 그의 용도
TW201817745A (zh) *	2011-09-30	2018-05-16	日商中外製藥股份有限公司	具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
WO2013047748A1 (fr)	2011-09-30	2013-04-04	中外製薬株式会社	Molécule se liant à l'antigène favorisant la disparition des antigènes ayant une pluralité d'activités biologiques
SG11201401101XA (en)	2011-09-30	2014-08-28	Chugai Pharmaceutical Co Ltd	Antigen-binding molecule for promoting loss of antigens
SG11201401100UA (en)	2011-09-30	2014-07-30	Chugai Pharmaceutical Co Ltd	Antigen-binding molecule inducing immune response to target antigen
JP6271251B2 (ja)	2011-10-05	2018-01-31	中外製薬株式会社	糖鎖受容体結合ドメインを含む抗原の血漿中からの消失を促進する抗原結合分子
AU2012323316B2 (en) *	2011-10-11	2017-08-10	Viela Bio, Inc.	CD40L-specific Tn3-derived scaffolds and methods of use thereof
SG10201609301QA (en)	2011-11-30	2016-12-29	Chugai Pharmaceutical Co Ltd	Drug containing carrier into cell for forming immune complex
KR102041412B1 (ko) *	2011-12-30	2019-11-11	한미사이언스 주식회사	면역글로불린 Ｆｃ 단편 유도체
HK1201296A1 (en)	2012-02-09	2015-08-28	中外制药株式会社	Modified fc region of antibody
MX2014009565A (es)	2012-02-10	2014-11-10	Genentech Inc	Anticuerpos monocatenarios y otros heteromultimeros.
ES2676031T3 (es)	2012-02-15	2018-07-16	F. Hoffmann-La Roche Ag	Cromatografía de afinidad basada en el receptor Fc
EP3738980A1 (fr)	2012-02-24	2020-11-18	Chugai Seiyaku Kabushiki Kaisha	Molécule de liaison d'antigène destinée à favoriser la disparition d'antigène via le récepteur fc riib
ES2856272T3 (es)	2012-05-30	2021-09-27	Chugai Pharmaceutical Co Ltd	Molécula de unión a antígenos para eliminar antígenos agregados
AU2013268418B2 (en)	2012-05-30	2017-12-07	Chugai Seiyaku Kabushiki Kaisha	Target-tissue-specific antigen-binding molecule
RU2015100656A (ru)	2012-06-27	2016-08-20	Ф. Хоффманн-Ля Рош Аг	Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения
ES2597228T3 (es)	2012-06-27	2017-01-17	F. Hoffmann-La Roche Ag	Procedimiento para la selección y la producción de entidades de objetivación, como dianas, altamente selectivas y multiespecíficas, personalizadas, las cuales contienen por lo menos dos entidades de unión diferentes, y utilización de éstas
EP3632462A1 (fr) *	2012-07-06	2020-04-08	Genmab B.V.	Protéine dimérique ayant des mutations triples
JP6514103B2 (ja) *	2012-07-06	2019-05-15	ゲンマブビー．ブイ．	三重変異を有する二量体タンパク質
WO2014009465A1 (fr)	2012-07-13	2014-01-16	Roche Glycart Ag	Anticorps bispécifiques anti-vegf/anti-ang-2 et leur utilisation dans le cadre du traitement de pathologies vasculaires oculaires
EP3597747B1 (fr)	2012-08-24	2023-03-15	Chugai Seiyaku Kabushiki Kaisha	Anticorps fc spécifiques fcgammarii de souris
SG11201500873XA (en)	2012-08-24	2015-04-29	Chugai Pharmaceutical Co Ltd	Fcgriib-specific fc region variant
ES2876009T3 (es)	2012-12-27	2021-11-11	Chugai Pharmaceutical Co Ltd	Polipéptido heterodimerizado
EA201500741A1 (ru) *	2013-01-10	2016-01-29	Генмаб Б.В.	ВАРИАНТЫ Fc-ОБЛАСТИ IGG1 ЧЕЛОВЕКА И ИХ ПРИМЕНЕНИЕ
EP2968495B1 (fr) *	2013-03-15	2019-07-03	Daniel J. Capon	Immunoglobuline hybride contenant une liaison non peptidique
KR102318483B1 (ko)	2013-04-02	2021-10-27	추가이 세이야쿠 가부시키가이샤	Ｆｃ영역 개변체
KR102266819B1 (ko) *	2013-04-29	2021-06-18	에프. 호프만-라 로슈 아게	Fc-수용체 결합 개질된 비대칭 항체 및 이의 사용 방법
WO2014177460A1 (fr)	2013-04-29	2014-11-06	F. Hoffmann-La Roche Ag	Anticorps modifiés se liant au fcrn humain et procédés d'utilisation
BR112016006929A2 (pt)	2013-10-11	2017-09-19	Hoffmann La Roche	Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
CN105916880B (zh)	2014-01-15	2020-01-17	豪夫迈·罗氏有限公司	具有改善的蛋白A结合作用的Fc区变体
NZ631007A (en)	2014-03-07	2015-10-30	Alexion Pharma Inc	Anti-c5 antibodies having improved pharmacokinetics
MX377605B (es)	2014-03-14	2025-03-10	Daniel J Capon	Inmunoglobulina híbrida conteniendo un enlace no-peptidílico.
WO2015140126A1 (fr)	2014-03-21	2015-09-24	F. Hoffmann-La Roche Ag	Prédiction in vitro de demi-vie in vivo d'anticorps
WO2015171822A1 (fr)	2014-05-06	2015-11-12	Genentech, Inc.	Production de protéines hétéromultimères au moyen de cellules mammaliennes
US9840553B2 (en)	2014-06-28	2017-12-12	Kodiak Sciences Inc.	Dual PDGF/VEGF antagonists
KR20170078677A (ko) *	2014-11-06	2017-07-07	에프. 호프만-라 로슈 아게	Fcrn-결합이 개질된 fc-영역 변이체 및 이의 사용 방법
WO2016087416A1 (fr)	2014-12-03	2016-06-09	F. Hoffmann-La Roche Ag	Anticorps multispécifiques
TWI779010B (zh)	2014-12-19	2022-10-01	日商中外製藥股份有限公司	抗肌抑素之抗體、含變異Ｆｃ區域之多胜肽及使用方法
CN114773470A (zh) *	2015-02-05	2022-07-22	中外制药株式会社	包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
FR3034420A1 (fr)	2015-03-31	2016-10-07	Lab Francais Du Fractionnement	Anticorps monoclonaux anti-cd303
KR102709693B1 (ko)	2015-12-18	2024-09-24	추가이 세이야쿠 가부시키가이샤	항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
WO2017110981A1 (fr)	2015-12-25	2017-06-29	Chugai Seiyaku Kabushiki Kaisha	Anticorps anti-myostatine et procédés d'utilisation
SG11201805420SA (en)	2015-12-30	2018-07-30	Kodiak Sciences Inc	Antibodies and conjugates thereof
PT3430039T (pt) *	2016-03-14	2026-01-16	Univ Oslo	Imunoglobulinas manipuladas com ligação a fcrn alterada
PL3429622T3 (pl) *	2016-03-14	2021-11-02	Biotest Ag	Leczenie ciężkiego pozaszpitalnego zapalenia płuc
KR20190012199A (ko)	2016-05-27	2019-02-08	알렉시온 파마슈티칼스, 인코포레이티드	난치성 전신 중증 근무력증의 치료를 위한 방법
EP3472200B1 (fr)	2016-06-17	2026-01-28	Chugai Seiyaku Kabushiki Kaisha	Anticorps anti-myostatine et leurs procédés d'utilisation
KR20190039937A (ko)	2016-07-08	2019-04-16	스태튼 바이오테크놀로지 비.브이.	항-ApoC3 항체 및 이의 사용 방법
DK3494134T3 (da) *	2016-08-02	2026-02-09	Visterra Inc	Manipulerede polypeptider og deres anvendelse
JP6527643B2 (ja)	2016-08-05	2019-06-05	中外製薬株式会社	Ｉｌ−８関連疾患の治療用又は予防用組成物
SG10201607778XA (en)	2016-09-16	2018-04-27	Chugai Pharmaceutical Co Ltd	Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
ES2902670T3 (es) *	2017-01-13	2022-03-29	Taizhou Hanzhong Biopharmaceutics Inc	Anticuerpo monoclonal contra PD-1 y aplicaciones del mismo
KR20190141659A (ko)	2017-04-21	2019-12-24	스태튼 바이오테크놀로지 비.브이.	항-apoc3 항체 및 이의 사용 방법
WO2018203545A1 (fr)	2017-05-02	2018-11-08	国立研究開発法人国立精神・神経医療研究センター	Procédé de prédiction et d'évaluation d'un effet thérapeutique dans des maladies associées à il-6 et à des neutrophiles
CN107748259A (zh) *	2017-07-26	2018-03-02	东曜药业有限公司	一种FcRn受体的ELISA检测方法
SI3658184T1 (sl)	2017-07-27	2024-01-31	Alexion Pharmaceuticals, Inc.,	Formulacije z visoko koncentracijo protiteles proti-C5
KR20240162603A (ko)	2017-10-26	2024-11-15	알렉시온 파마슈티칼스, 인코포레이티드	발작성 야간 혈색소뇨 (pnh) 및 비정형 용혈성 요독 증후군 (ahus)의 치료를 위한 항-c5 항체의 투여량 및 투여
US10538583B2 (en)	2017-10-31	2020-01-21	Staten Biotechnology B.V.	Anti-APOC3 antibodies and compositions thereof
EP3704148A1 (fr)	2017-10-31	2020-09-09	Staten Biotechnology B.V.	Anticorps anti-apoc3 et leurs procédés d'utilisation
US12084513B2 (en)	2017-11-14	2024-09-10	Chugai Seiyaku Kabushiki Kaisha	Anti-C1S antibodies and methods of use
EP3498293A1 (fr)	2017-12-15	2019-06-19	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Traitement de maladies monogéniques avec un anticorps anti-cd45rc
FR3076294B1 (fr)	2017-12-29	2022-01-28	Lab Francais Du Fractionnement	Procede de purification d'anticorps a partir de lait brut
CN108101992B (zh) *	2017-12-31	2021-03-26	武汉班科生物技术股份有限公司	与新生的Fc受体结合增强的CH2结构域突变体及其制备方法与应用
JP2018138022A (ja) *	2018-02-23	2018-09-06	ゲンマブビー．ブイ．	ヒトＩｇＧ１Ｆｃ領域変異体およびその使用
WO2019169341A1 (fr)	2018-03-02	2019-09-06	Kodiak Sciences Inc.	Anticorps anti-il-6 et constructions de fusion et conjugués associés
US20200040103A1 (en)	2018-03-14	2020-02-06	Genentech, Inc.	Anti-klk5 antibodies and methods of use
EP3765494A4 (fr)	2018-03-15	2022-03-23	Chugai Seiyaku Kabushiki Kaisha	Anticorps dirigés contre le virus de la dengue présentant une réactivité croisée au virus zika et procédés d'utilisation
CN108519383B (zh) *	2018-04-08	2020-08-14	上海理工大学	一种全波段生物显色实验的检测方法
US12404320B2 (en)	2018-05-31	2025-09-02	Alexion Pharmaceuticals, Inc.	Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients
US20210238308A1 (en) *	2018-06-04	2021-08-05	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule showing changed half-life in cytoplasm
US12460012B2 (en)	2018-06-04	2025-11-04	Alexion Pharmaceuticals, Inc.	Dosage and administration of anti-C5 antibodies for treatment of atypical hemolytic uremic syndrome (aHUS) in pediatric patients
EP3810185A4 (fr) *	2018-06-22	2022-03-23	Cugene Inc.	Variants d'interleukine-2 et leurs procédés d'utilisation
WO2020006266A1 (fr)	2018-06-28	2020-01-02	Alexion Pharmaceuticals, Inc.	Procédés de production d'anticorps anti-c5
SG11202003531WA (en)	2018-08-10	2020-05-28	Chugai Pharmaceutical Co Ltd	Anti-cd137 antigen-binding molecule and utilization thereof
CN112930194B (zh)	2018-10-29	2024-08-09	豪夫迈·罗氏有限公司	抗体制剂
BR112021008063A2 (pt)	2018-10-30	2021-08-10	Alexion Pharmaceuticals, Inc.	dosagem subcutânea e administração de anticorpos anti-c 5 para tratamento de hemoglobinúria paroxística noturna (pnh)
WO2020152290A1 (fr)	2019-01-23	2020-07-30	Encefa	Compétiteurs de cd31 et utilisations associées
EP3969475A4 (fr)	2019-05-15	2023-04-26	Chugai Seiyaku Kabushiki Kaisha	Molécule de liaison à un antigène, composition pharmaceutique et procédé
AR119997A1 (es)	2019-09-18	2022-01-26	Genentech Inc	Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso
MX2022003316A (es) *	2019-09-18	2022-07-11	Momenta Pharmaceuticals Inc	Composiciones y métodos relacionados con constructos de fc-dominio de unión al antígeno diseñados por ingeniería dirigidos a cd38.
EP4041312A4 (fr)	2019-10-10	2023-12-20	Kodiak Sciences Inc.	Procédés de traitement d'un trouble oculaire
US11739142B2 (en)	2019-12-18	2023-08-29	Hoffmann-La Roche Inc.	Bispecific anti-CCL2 antibodies
CN113637084B (zh) *	2020-05-11	2025-08-01	上海康景生物医药科技有限公司	生物大分子靶向特异性补体抑制剂及其制备方法与应用
AU2022295067A1 (en)	2021-06-18	2023-12-21	F. Hoffmann-La Roche Ag	Bispecific anti-ccl2 antibodies
EP4581059A2 (fr) *	2022-09-02	2025-07-09	Zoetis Services LLC	Mutants d'anticorps équins
CN121319170A (zh) *	2024-07-12	2026-01-13	菲鹏生物股份有限公司	免疫球蛋白及其用途

Family Cites Families (141)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
CU22545A1 (es)	1994-11-18	1999-03-31	Centro Inmunologia Molecular	Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
FR2413974A1 (fr)	1978-01-06	1979-08-03	David Bernard	Sechoir pour feuilles imprimees par serigraphie
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4675187A (en)	1983-05-16	1987-06-23	Bristol-Myers Company	BBM-1675, a new antibiotic complex
US4943533A (en)	1984-03-01	1990-07-24	The Regents Of The University Of California	Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5004697A (en)	1987-08-17	1991-04-02	Univ. Of Ca	Cationized antibodies for delivery through the blood-brain barrier
JP3040121B2 (ja)	1988-01-12	2000-05-08	ジェネンテク，インコーポレイテッド	増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5047335A (en) *	1988-12-21	1991-09-10	The Regents Of The University Of Calif.	Process for controlling intracellular glycosylation of proteins
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DK0479909T3 (da)	1989-06-29	1997-04-07	Medarex Inc	Bispecifikke reagenser til AIDS-behandling
ES2284161T3 (es)	1990-01-12	2007-11-01	Amgen Fremont Inc.	Generacion de anticuerpos xenogenicos.
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5268164A (en)	1990-04-23	1993-12-07	Alkermes, Inc.	Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en)	1990-04-23	1992-05-12	Alkermes, Inc.	Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
ES2162789T3 (es)	1990-06-29	2002-01-16	Large Scale Biology Corp	Produccion de melanina por microorganismos transformados.
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
CA2089661C (fr)	1990-08-29	2007-04-03	Nils Lonberg	Animaux transgeniques non humains capables de produire des anticorps heterologues
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
CZ283717B6 (cs)	1991-03-06	1998-06-17	MERCK Patent Gesellschaft mit beschränkter Haftung	Chimérická monoklonální protilátka, expresní vektory a farmaceutický prostředek
US5278299A (en) *	1991-03-18	1994-01-11	Scripps Clinic And Research Foundation	Method and composition for synthesizing sialylated glycosyl compounds
US6582959B2 (en)	1991-03-29	2003-06-24	Genentech, Inc.	Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en)	1991-03-29	2003-11-06	Genentech, Inc.	Vascular endothelial cell growth factor antagonists
AU675916B2 (en)	1991-06-14	1997-02-27	Genentech Inc.	Method for making humanized antibodies
WO1994004679A1 (fr)	1991-06-14	1994-03-03	Genentech, Inc.	Procede pour fabriquer des anticorps humanises
GB9114948D0 (en)	1991-07-11	1991-08-28	Pfizer Ltd	Process for preparing sertraline intermediates
DE69229477T2 (de)	1991-09-23	1999-12-09	Cambridge Antibody Technology Ltd., Melbourn	Methoden zur Herstellung humanisierter Antikörper
WO1993008829A1 (fr)	1991-11-04	1993-05-13	The Regents Of The University Of California	Compositions induisant la destruction de cellules infectees par l'hiv
AU3144193A (en) *	1991-11-21	1993-06-15	Board Of Trustees Of The Leland Stanford Junior University	Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
DE69328430T2 (de)	1992-07-27	2001-01-25	The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer	Zielgerichte liposome zur blut-hirne schranke
ATE149570T1 (de)	1992-08-17	1997-03-15	Genentech Inc	Bispezifische immunoadhesine
DK1167384T3 (da)	1992-10-28	2007-04-10	Genentech Inc	Vaskular endotheliel cellevækstfaktor antagonister
GB9401182D0 (en)	1994-01-21	1994-03-16	Inst Of Cancer The Research	Antibodies to EGF receptor and their antitumour effect
US5635388A (en)	1994-04-04	1997-06-03	Genentech, Inc.	Agonist antibodies against the flk2/flt3 receptor and uses thereof
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
IL117645A (en)	1995-03-30	2005-08-31	Genentech Inc	Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5641870A (en)	1995-04-20	1997-06-24	Genentech, Inc.	Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en)	1995-04-14	1999-02-09	Genentech, Inc.	Altered polypeptides with increased half-life
US5747035A (en)	1995-04-14	1998-05-05	Genentech, Inc.	Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US6096871A (en)	1995-04-14	2000-08-01	Genentech, Inc.	Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
EP0822830B1 (fr)	1995-04-27	2008-04-02	Amgen Fremont Inc.	Anticorps anti-IL-8 dérivés de xenosouris immunisées
AU2466895A (en)	1995-04-28	1996-11-18	Abgenix, Inc.	Human antibodies derived from immunized xenomice
AU6267896A (en)	1995-06-07	1996-12-30	Imclone Systems Incorporated	Antibody and antibody fragments for inhibiting the growth oftumors
GB9603256D0 (en)	1996-02-16	1996-04-17	Wellcome Found	Antibodies
CA2249195A1 (fr) *	1996-03-18	1997-09-25	Board Of Regents, The University Of Texas System	Domaines analogues a l'immunoglobuline a demi-vies prolongees
WO1997043316A1 (fr)	1996-05-10	1997-11-20	Beth Israel Deaconess Medical Center, Inc.	Molecules physiologiquement actives a demi-vies prolongees et methode d'utilisation de ces dernieres
DE69738539T2 (de)	1996-12-03	2009-03-26	Amgen Fremont Inc.	Vollkommen humane Antikörper die EGFR binden
US20020032315A1 (en)	1997-08-06	2002-03-14	Manuel Baca	Anti-vegf antibodies
DE122005000026I1 (de)	1997-04-07	2005-08-04	Genentech Inc	Anti-VEGF Antik¦rper.
DK1695985T3 (da)	1997-04-07	2011-06-14	Genentech Inc	Fremgangsmåde til dannelse af humaniserede antistoffer ved tilfældig mutagenese
US6884879B1 (en)	1997-04-07	2005-04-26	Genentech, Inc.	Anti-VEGF antibodies
WO1998048032A2 (fr)	1997-04-21	1998-10-29	Donlar Corporation	ACIDE POLY-α-L-ASPARTIQUE, ACIDE-POLY-α-L-GLUTAMIQUE ET COPOLYMERES DE L-ASP ET L-GLU, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
DE69830315T2 (de)	1997-06-24	2006-02-02	Genentech Inc., San Francisco	Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
US20040191256A1 (en) *	1997-06-24	2004-09-30	Genentech, Inc.	Methods and compositions for galactosylated glycoproteins
US6172213B1 (en) *	1997-07-02	2001-01-09	Genentech, Inc.	Anti-IgE antibodies and method of improving polypeptides
AU759779B2 (en)	1997-10-31	2003-05-01	Genentech Inc.	Methods and compositions comprising glycoprotein glycoforms
CA2312208C (fr)	1997-12-05	2011-01-25	The Scripps Research Institute	Humanisation d'anticorps murins
US6194551B1 (en) *	1998-04-02	2001-02-27	Genentech, Inc.	Polypeptide variants
US6528624B1 (en) *	1998-04-02	2003-03-04	Genentech, Inc.	Polypeptide variants
IL138608A0 (en)	1998-04-02	2001-10-31	Genentech Inc	Antibody variants and fragments thereof
JP4334141B2 (ja)	1998-04-20	2009-09-30	グリカートバイオテクノロジーアクチェンゲゼルシャフト	抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
CN1260249C (zh)	1998-05-06	2006-06-21	基因技术股份有限公司	用离子交换层析纯化蛋白质
PL209786B1 (pl) *	1999-01-15	2011-10-31	Genentech Inc	Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
US7183387B1 (en) *	1999-01-15	2007-02-27	Genentech, Inc.	Polypeptide variants with altered effector function
US6737056B1 (en) *	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
PT1914244E (pt) *	1999-04-09	2013-07-26	Kyowa Hakko Kirin Co Ltd	Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico
US6703020B1 (en)	1999-04-28	2004-03-09	Board Of Regents, The University Of Texas System	Antibody conjugate methods for selectively inhibiting VEGF
JP4668498B2 (ja)	1999-10-19	2011-04-13	協和発酵キリン株式会社	ポリペプチドの製造方法
JP2003523771A (ja)	2000-02-25	2003-08-12	ザガバメントオブザユナイテッドステイツ，アズレプレゼンテッドバイザセクレタリーオブザデパートメントオブヘルスアンドヒューマンサービシーズ	改善された細胞傷害性および収率を有する抗ＥＧＦＲｖＩＩＩｓｃＦｖ、それに基づく免疫毒素、ならびにその使用方法
US7449443B2 (en)	2000-03-23	2008-11-11	California Institute Of Technology	Method for stabilization of proteins using non-natural amino acids
AU5345901A (en) *	2000-04-13	2001-10-30	Univ Rockefeller	Enhancement of antibody-mediated immune responses
JP2003533987A (ja)	2000-05-19	2003-11-18	イスケミカルカンパニーリミテッド	表皮成長因子収容体に対するヒト化抗体
US6586207B2 (en)	2000-05-26	2003-07-01	California Institute Of Technology	Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
MEP13708A (en)	2000-06-23	2010-06-10	Bayer Schering Pharma Ag	Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii)
US7598055B2 (en) *	2000-06-28	2009-10-06	Glycofi, Inc.	N-acetylglucosaminyltransferase III expression in lower eukaryotes
US6514221B2 (en)	2000-07-27	2003-02-04	Brigham And Women's Hospital, Inc.	Blood-brain barrier opening
US20020065259A1 (en)	2000-08-30	2002-05-30	Schatzberg Alan F.	Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US6946292B2 (en)	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en)	2000-10-06	2006-06-20	Kyowa Hakko Kogyo Co., Ltd.	Process for purifying antibody
WO2002031140A1 (fr)	2000-10-06	2002-04-18	Kyowa Hakko Kogyo Co., Ltd.	Cellules produisant des compositions d'anticorps
US7034036B2 (en)	2000-10-30	2006-04-25	Pain Therapeutics, Inc.	Inhibitors of ABC drug transporters at the blood-brain barrier
US20030083299A1 (en)	2000-11-04	2003-05-01	Ferguson Ian A.	Non-invasive delivery of polypeptides through the blood-brain barrier
US6480405B2 (en) *	2000-11-17	2002-11-12	Texas Instruments Incorporated	Full-wave rectifier
US7083784B2 (en) *	2000-12-12	2006-08-01	Medimmune, Inc.	Molecules with extended half-lives, compositions and uses thereof
CN1911965B (zh) *	2001-01-17	2013-05-29	新兴产品开发西雅图有限公司	结合域-免疫球蛋白融合蛋白
AU2002250352C1 (en) *	2001-04-02	2009-04-30	Genentech, Inc.	Combination therapy
DE10121982B4 (de)	2001-05-05	2008-01-24	Lts Lohmann Therapie-Systeme Ag	Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
CA2450700A1 (fr)	2001-06-14	2002-12-27	Isis Innovation Limited	Anticorps trx1 et utilisations connexes
ATE445838T1 (de)	2001-07-25	2009-10-15	Raptor Pharmaceutical Inc	Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
IL160170A0 (en)	2001-08-03	2004-07-25	Glycart Biotechnology Ag	A host cell engineered to produce a polypeptide having increased cytotoxicity
DK1443961T3 (da) *	2001-10-25	2009-08-24	Genentech Inc	Glycoprotein-sammensætninger
US20040093621A1 (en) *	2001-12-25	2004-05-13	Kyowa Hakko Kogyo Co., Ltd	Antibody composition which specifically binds to CD20
AU2003248370A1 (en)	2002-02-27	2003-09-09	California Institute Of Technology	Computational method for designing enzymes for incorporation of amino acid analogs into proteins
US20030162695A1 (en)	2002-02-27	2003-08-28	Schatzberg Alan F.	Glucocorticoid blocking agents for increasing blood-brain barrier permeability
WO2003085119A1 (fr)	2002-04-09	2003-10-16	Kyowa Hakko Kogyo Co., Ltd.	Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fc$g(g) iiia
AU2003236015A1 (en)	2002-04-09	2003-10-20	Kyowa Hakko Kirin Co., Ltd.	Process for producing antibody composition
AU2003236017B2 (en)	2002-04-09	2009-03-26	Kyowa Kirin Co., Ltd.	Drug containing antibody composition
US7749753B2 (en)	2002-04-09	2010-07-06	Kyowa Hakko Kirin Co., Ltd	Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost
CA2481925A1 (fr)	2002-04-09	2003-10-16	Kyowa Hakko Kogyo Co., Ltd.	Agent therapeutique pour les patients atteints du fc.gamma.riiia humain
KR20050000380A (ko)	2002-04-09	2005-01-03	교와 핫꼬 고교 가부시끼가이샤	게놈이 개변된 세포
AU2003267905B2 (en)	2002-10-04	2009-02-05	Biolnvent International Ab	Peptide-based passive immunization therapy for treatment of atherosclerosis
SE0302312D0 (sv)	2002-10-04	2003-08-27	Forskarpatent I Syd Ab	Peptide-based passive immunization therapy for treatment of atherosclerosis
US7217797B2 (en)	2002-10-15	2007-05-15	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004050062A2 (fr)	2002-12-03	2004-06-17	Blanchette Rockefeller Neurosciences Institute	Porteurs artificiels a base de lipoproteines basse densite pour le transport de substances a travers la barriere hemato-encephalique
WO2004056312A2 (fr) *	2002-12-16	2004-07-08	Genentech, Inc.	Variants d'immunoglobuline et utilisations
ES2897506T3 (es) *	2003-01-09	2022-03-01	Macrogenics Inc	Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos
WO2004113304A1 (fr)	2003-05-22	2004-12-29	Abbott Laboratories	Inhibiteurs de kinases de type indazole, benzisoxazole et benzisothiazole
RS20181002A1 (sr)	2003-05-30	2018-12-31	Genentech Inc	Tretman sa anti-vegf antitelima
US20050106667A1 (en)	2003-08-01	2005-05-19	Genentech, Inc	Binding polypeptides with restricted diversity sequences
WO2005044853A2 (fr)	2003-11-01	2005-05-19	Genentech, Inc.	Anticorps anti-vegf
US7758859B2 (en)	2003-08-01	2010-07-20	Genentech, Inc.	Anti-VEGF antibodies
JP2007505142A (ja)	2003-09-10	2007-03-08	セダーズ−シナイメディカルセンター	血液脳関門を通過する薬剤のカリウムチャネル媒介性送達
JPWO2005035586A1 (ja)	2003-10-08	2007-11-22	協和醗酵工業株式会社	融合蛋白質組成物
EP2322569B1 (fr)	2003-10-09	2020-08-26	Ambrx, Inc.	Dérivés de polymère pour la modification selective de proteines
US20070134759A1 (en)	2003-10-09	2007-06-14	Harue Nishiya	Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase
DK2380910T3 (en)	2003-11-05	2015-10-19	Roche Glycart Ag	Antigen binding molecules with increased Fc receptor binding affinity and effector function
JPWO2005053742A1 (ja)	2003-12-04	2007-06-28	協和醗酵工業株式会社	抗体組成物を含有する医薬
US7118999B2 (en) *	2004-01-16	2006-10-10	International Business Machines Corporation	Method and apparatus to increase strain effect in a transistor channel
MXPA06008496A (es)	2004-02-02	2007-01-30	Ambrx Inc	Polipeptidos de interferon humano modificados y sus usos.
US20060009360A1 (en)	2004-06-25	2006-01-12	Robert Pifer	New adjuvant composition
CN101189028B (zh) *	2004-07-12	2013-05-29	马克罗基因公司	具有变异Fc区的抗体的鉴定和工程化以及使用方法
JP5055603B2 (ja) *	2004-08-04	2012-10-24	メントリック・バイオテック・リミテッド・ライアビリティ・カンパニー	変異Ｆｃ領域
CN101052654A (zh) *	2004-08-19	2007-10-10	健泰科生物技术公司	具有改变的效应子功能的多肽变体
US8802820B2 (en) *	2004-11-12	2014-08-12	Xencor, Inc.	Fc variants with altered binding to FcRn
RU2412200C2 (ru) *	2004-11-12	2011-02-20	Ксенкор, Инк.	Fc-ВАРИАНТЫ С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ С FcRn
US8367805B2 (en) *	2004-11-12	2013-02-05	Xencor, Inc.	Fc variants with altered binding to FcRn
CA2587617C (fr) *	2004-11-12	2011-02-01	Xencor, Inc.	Variants fc presentant une liaison modifiee au fcrn
CN101120021A (zh)	2004-12-31	2008-02-06	基因技术公司	结合br3的多肽及其用途
DE602005026067D1 (de) *	2005-09-07	2011-03-03	Palcan Y Bin S L	Dreidimensionales puzzle
WO2007109052A2 (fr) *	2006-03-16	2007-09-27	Genentech, Inc.	procedes de traitement du lupus au moyen d'anticorps cd4
WO2008140603A2 (fr) *	2006-12-08	2008-11-20	Macrogenics, Inc.	MÉTHODES POUR LE TRAITEMENT DE MALADIE AU MOYEN D'IMMUNOGLOBULINES COMPRENANT DES RÉGIONS FC QUI PRÉSENTENT DES AFFINITÉS ALTÉRÉES POUR FCγR D'ACTIVATION ET FCγR D'INHIBITION
TWI468417B (zh)	2007-11-30	2015-01-11	Genentech Inc	抗－ｖｅｇｆ抗體
CA3086659A1 (fr) *	2007-12-26	2009-07-09	Xencor, Inc.	Variants de fc avec une liaison alteree a fcrn

2009
- 2009-10-13 SG SG10201605250SA patent/SG10201605250SA/en unknown
- 2009-10-13 EP EP09793631.4A patent/EP2352521B1/fr active Active
- 2009-10-13 KR KR1020187005799A patent/KR102100066B1/ko not_active Expired - Fee Related
- 2009-10-13 MX MX2011004001A patent/MX2011004001A/es active IP Right Grant
- 2009-10-13 TW TW104123461A patent/TWI572359B/zh not_active IP Right Cessation
- 2009-10-13 ES ES09793631T patent/ES2828721T3/es active Active
- 2009-10-13 JP JP2011531249A patent/JP5913980B2/ja not_active Expired - Fee Related
- 2009-10-13 PL PL09793631T patent/PL2352521T3/pl unknown
- 2009-10-13 KR KR1020117010964A patent/KR101834999B1/ko not_active Expired - Fee Related
- 2009-10-13 BR BRPI0914091-3A patent/BRPI0914091B1/pt not_active IP Right Cessation
- 2009-10-13 EP EP18212252.3A patent/EP3524620A1/fr not_active Withdrawn
- 2009-10-13 CA CA2739429A patent/CA2739429C/fr active Active
- 2009-10-13 US US12/577,967 patent/US20100098730A1/en not_active Abandoned
- 2009-10-13 SG SG2013076815A patent/SG195558A1/en unknown
- 2009-10-13 CN CN201910548858.4A patent/CN110317272A/zh active Pending
- 2009-10-13 CN CN200980150204.0A patent/CN102245208B/zh not_active Expired - Fee Related
- 2009-10-13 AU AU2009303526A patent/AU2009303526B2/en not_active Ceased
- 2009-10-13 WO PCT/US2009/060443 patent/WO2010045193A1/fr not_active Ceased
- 2009-10-13 CN CN201410562388.4A patent/CN104447990B/zh not_active Expired - Fee Related
- 2009-10-13 TW TW098134687A patent/TWI572357B/zh not_active IP Right Cessation
- 2009-10-13 KR KR1020197005957A patent/KR20190025057A/ko not_active Withdrawn
- 2009-10-13 RU RU2011119447/10A patent/RU2536937C2/ru active
- 2009-10-13 PE PE2015000431A patent/PE20150682A1/es active IP Right Grant
- 2009-10-13 PE PE2011000886A patent/PE20110707A1/es active IP Right Grant
- 2009-10-13 AR ARP090103925A patent/AR073829A1/es not_active Application Discontinuation
2011
- 2011-03-31 IL IL212048A patent/IL212048B/en active IP Right Grant
- 2011-03-31 ZA ZA2011/02413A patent/ZA201102413B/en unknown
2014
- 2014-02-24 US US14/188,432 patent/US20140294810A1/en not_active Abandoned
2015
- 2015-01-21 CL CL2015000148A patent/CL2015000148A1/es unknown
- 2015-07-24 JP JP2015146850A patent/JP6122072B2/ja not_active Expired - Fee Related
2016
- 2016-01-12 PH PH12016500081A patent/PH12016500081A1/en unknown
2019
- 2019-01-08 IL IL264138A patent/IL264138A/en unknown
2020
- 2020-06-01 US US16/889,510 patent/US20210002359A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2739429C (fr)	2020-12-22
CN102245208B (zh)	2016-03-16
AU2009303526B2 (en)	2015-01-15
CN104447990A (zh)	2015-03-25
ZA201102413B (en)	2012-06-27
JP6122072B2 (ja)	2017-04-26
CN102245208A (zh)	2011-11-16
TW201542228A (zh)	2015-11-16
CN110317272A (zh)	2019-10-11
PL2352521T3 (pl)	2021-03-08
JP2012505833A (ja)	2012-03-08
PH12016500081B1 (en)	2017-01-16
CN104447990B (zh)	2019-07-19
HK1163550A1 (zh)	2012-09-14
US20210002359A1 (en)	2021-01-07
KR101834999B1 (ko)	2018-03-06
KR20180027609A (ko)	2018-03-14
BRPI0914091B1 (pt)	2022-05-10
ES2828721T3 (es)	2021-05-27
US20100098730A1 (en)	2010-04-22
TWI572357B (zh)	2017-03-01
IL212048B (en)	2020-02-27
EP2352521B1 (fr)	2020-09-16
US20140294810A1 (en)	2014-10-02
JP5913980B2 (ja)	2016-05-11
WO2010045193A1 (fr)	2010-04-22
AU2009303526A1 (en)	2010-04-22
IL212048A0 (en)	2011-06-30
EP3524620A1 (fr)	2019-08-14
PH12016500081A1 (en)	2017-01-16
SG195558A1 (en)	2013-12-30
BRPI0914091A2 (pt)	2016-09-27
MX2011004001A (es)	2011-05-19
HK1209130A1 (en)	2016-03-24
EP2352521A1 (fr)	2011-08-10
AR073829A1 (es)	2010-12-01
KR20110070914A (ko)	2011-06-24
CA2739429A1 (fr)	2010-04-22
RU2011119447A (ru)	2012-11-27
PE20110707A1 (es)	2011-10-11
KR102100066B1 (ko)	2020-04-10
TWI572359B (zh)	2017-03-01
IL264138A (en)	2019-02-28
TW201023884A (en)	2010-07-01
RU2536937C2 (ru)	2014-12-27
KR20190025057A (ko)	2019-03-08
CL2015000148A1 (es)	2015-04-24
SG10201605250SA (en)	2016-08-30
JP2016026144A (ja)	2016-02-12

Publication	Publication Date	Title
PE20150682A1 (es)	2015-05-20	Variantes de inmunoglobulinas y sus usos
PL2358756T3 (pl)	2017-06-30	Ludzkie przeciwciała o wysokim powinowactwie wobec pcsk9
EP2173377A4 (fr)	2011-12-14	Protéine de fusion anticorps-endostatine et ses variants
DK2388266T3 (da)	2014-05-26	Fusionsmolekyler og IL-15-varianter
BRPI0920909A2 (pt)	2015-12-29	composições de cuidados pessoais que fornecem sensação fe resfriamento intensificada.
CY2016029I2 (el)	2017-04-26	Πρωτεϊνες συνδεσης αντιγονου προς προπρωτεϊνη κονβερτασης σουμπτιλισινης κεχιν τυπου 9(pcsk9)
BRPI0913574A2 (pt)	2015-11-24	composição de tratamento de acne compreendendo nanoprata e usos
DK1962886T4 (da)	2022-05-02	Stabile proteinformuleringer
CR10889A (es)	2009-09-01	Antagonistas de activina-actrii y sus usos para incrementar los niveles de globulos rojos en la sangre
EP2023941A4 (fr)	2013-05-08	Agents de réticulation de protéine, méthodes de réticulation et leurs applications
MX338884B (es)	2016-05-04	Composiciones y metodos que comprenden variantes de proteasa.
DK1866339T3 (da)	2013-09-02	GTR-bindende molekyler og anvendelser heraf
PT1971366E (pt)	2014-11-06	Anticorpos humanos anti-il-23, composições, métodos e usos
DE502007001405D1 (de)	2009-10-08	Haarpflegezusammensetzung
BRPI0919519A2 (pt)	2015-08-18	Composição, agente herbicida, e, usos de herbicida, e da composição
BRPI0819714A2 (pt)	2015-05-26	Formulações de proteína e métodos de produção das mesmas.
BRPI0913447A2 (pt)	2015-12-01	composição de éster, e, composição para cuidado pessoal.
DK2283041T3 (da)	2015-12-07	Humaniserede anti-faktor d-antistoffer og anvendelser deraf
PT2061814E (pt)	2012-09-10	Anticorpos e imunoconjugados e suas utilizações
DK2352509T3 (da)	2013-08-12	Hla-g-proteiner og farmaceutiske anvendelser deraf
DK2491453T3 (da)	2013-08-12	Stang til briller og briller omfattende stangen
ATE481984T1 (de)	2010-10-15	Vakzine-peptid-kombinationen gegen katzenallergie
DK2344146T3 (da)	2013-07-08	Anticonnexin-midler til anvendelse til modulering af psykotrope molekylers terapeutiske virkning
EP2209114A4 (fr)	2011-09-28	Codeur et décodeur
CL2008002709A1 (es)	2008-10-24	Bacteria de mycoplasma atenuada que exhibe expresion reducida de una o mas proteinas del grupo piruvato deshidroxigenasa, fosfopiruvato hidratasa, 2-desoxirribosa-5-fosfato aldolasa y proteina l35 ribosomica; composicion de vacuna que la comprende; m

Legal Events

Date	Code	Title	Description
2019-08-15	FG	Grant, registration